In a country where advanced diagnostics are often a luxury, a Bengaluru startup is betting that the same gene-editing technology that won a Nobel Prize can be made cheap and simple enough for a rural clinic. CrisprBits, founded in 2020, is building a suite of CRISPR-based tools, but its immediate focus is on a platform called PathCrisp: a rapid, point-of-need diagnostic system designed to detect diseases like sickle cell anemia and typhoid with a speed and affordability that conventional lab tests struggle to match [PERPLEXITY SONAR PRO BRIEF]. The company’s recent $3 million pre-Series A, led by Spectrum Impact, values the firm at $12 million and is earmarked to scale manufacturing for commercial rollout [Indian Startup Times, 2025]. For a team of BITS Pilani alumni, the goal is not just scientific novelty, but pervasive accessibility.
A Platform Built on Three Pillars
CrisprBits is structured as a platform-first company, an approach that spreads its CRISPR expertise across three distinct but connected product lines. This allows the team to pursue near-term revenue while funding longer-term, more ambitious research.
- PathCrisp: The Diagnostic Wedge. This is the commercial spearhead. It’s a molecular diagnostic system using CRISPR to identify specific genetic markers for infectious diseases and genetic disorders. The initial targets are high-burden conditions in India: sickle cell disease, typhoid, and antimicrobial resistance (AMR) [PERPLEXITY SONAR PRO BRIEF]. The company claims the kits offer higher precision at a lower cost than conventional tests, with a design emphasis on user-friendliness for settings with limited lab infrastructure.
- EdiCrisp: The Industrial Play. This platform applies CRISPR gene-editing tools to optimize organisms for industrial processes. The first publicly cited application is in biofuel production, where editing microbial genes could improve yield and efficiency [Express Healthcare, 2025]. This represents a potential B2B revenue stream distinct from the healthcare diagnostics market.
- CurieCrisp: The Therapeutic Horizon. Framed as a longer-term initiative, this pillar aims at developing CRISPR-based therapies to cure genetic disorders. It is the most forward-looking of the three and sits firmly in the preclinical research domain [PERPLEXITY SONAR PRO BRIEF].
The strategic bet is clear. PathCrisp generates the near-term traction and revenue in a large, underserved market. Success there funds and de-risks the development of the higher-margin, but more complex and regulated, industrial and therapeutic arms.
The Team and Its Traction
CrisprBits was founded by five alumni from BITS Pilani, bringing together backgrounds in biotech, engineering, and academia [PERPLEXITY SONAR PRO BRIEF]. While specific titles are fluid in public records, key figures bring substantial credibility. Co-founder Vijay Chandru, also listed as Chief Scientific Officer, is a known entity in Indian biotech as the co-founder of Strand Life Sciences, a bioinformatics company with a two-decade history [Forbes, 2011]. Another co-founder, Sunil Arora, brings a formidable public-sector profile from his tenure as India’s Chief Election Commissioner [Bloomberg, 2019]. This blend of deep scientific and operational experience with high-level institutional understanding is a non-trivial asset for a company navigating India’s complex healthcare and regulatory landscape. The team has grown to 13 individuals, according to a recent report [Inc42].
Commercial traction is beginning to materialize. A significant validation came in the form of a partnership with Molbio Diagnostics, a major player in Indian point-of-care testing known for its portable PCR devices [Digital Health News]. This deal is focused on co-developing and distributing CRISPR-based point-of-care tests, effectively plugging PathCrisp into an existing and respected distribution channel. The company has also been incubated at C-CAMP, a government-backed biotech incubator, providing early-stage support and credibility [Crunchbase].
| Founder | Notable Background |
|---|---|
| Vijay Chandru | Co-founder & CSO; Co-founder of Strand Life Sciences [Forbes, 2011] |
| Sunil Arora | Former Chief Election Commissioner of India [Bloomberg, 2019] |
| Rajeev Kohli | Professor (University of Pittsburgh) [Crunchbase] |
| Bharat Jobanputra | Former VP Projects, Forderanlagen Magdeburg GmbH [crisprbits.com] |
| Aditya Sarda | Co-founder [Business Standard, 2025] |
The Regulatory and Commercial Path Ahead
For any diagnostic claiming clinical use, regulatory clearance is the gatekeeper. CrisprBits has not yet publicized submissions to India’s Central Drugs Standard Control Organization (CDSCO) or other agencies, which will be a critical milestone to watch. The company’s emphasis on affordability and point-of-need use aligns with public health priorities, potentially smoothing the path for adoption in government screening programs, especially for sickle cell disease, which is a focus of a national mission in India.
The $3 million in new capital is a meaningful war chest for a capital-efficient biotech startup in India, but it is also a modest sum for the dual challenges of scaling manufacturing and funding R&D across three platforms. The company will need to demonstrate that PathCrisp can achieve volume production at its promised low cost points. Furthermore, the diagnostic market, while large, is competitive. Established players like Molbio (also a partner) and Mylab have significant market share with PCR-based systems. CrisprBits’ differentiation hinges on CRISPR’s potential for faster, simpler, and cheaper tests, a claim that must now be proven at scale in real-world settings.
A Focus on Sickle Cell and Beyond
CrisprBits’ initial diagnostic targets are not chosen at random. They represent areas of high unmet need where a rapid, affordable test could change clinical pathways. Take sickle cell disease, a genetic blood disorder that disproportionately affects tribal populations in India. Current diagnosis often relies on lab-based techniques like hemoglobin electrophoresis, which requires specialized equipment and trained technicians, creating access barriers in remote areas. A point-of-care CRISPR test could enable widespread screening and earlier intervention, a goal squarely in line with the Indian government’s public health agenda.
The standard of care today for many of these conditions involves a delay. A patient with suspected typhoid may wait days for culture results, during which time broad-spectrum antibiotics are often prescribed, fueling antimicrobial resistance. A test that delivers a result in minutes, not days, at the point of care, could make treatment more precise and curb unnecessary antibiotic use. This is the patient outcome CrisprBits is ultimately chasing: turning complex genomic medicine into a simple, accessible tool for the clinics that need it most.
The next twelve months will be about translation. The capital from Spectrum Impact and others is intended to move PathCrisp from development to commercial scale [IndiaMedToday, 2025]. Success will be measured in kits shipped, partnerships expanded beyond Molbio, and, crucially, the first regulatory nods. If CrisprBits can navigate this path, it won’t just be selling a new diagnostic. It will be proving that frontier biotech can be engineered for equity, starting in India and aiming for a world of clinics waiting for a better test.
Sources
- [PERPLEXITY SONAR PRO BRIEF] CrisprBits company overview and product details
- [Indian Startup Times, 2025] Biotech startup CrisprBits raises $3 million to scale its CRISPR platforms | https://indianstartupnews.com/funding/biotech-startup-crisprbits-raises-3-million-to-scale-its-crispr-platforms-for-diagnostics-and-gene-editing-10810394
- [Express Healthcare, 2025] CrisprBits developing CRISPR-driven strain engineering platform
- [Forbes, 2011] Deal Boost for Biocon (references Strand Life Sciences) | https://www.forbes.com/2011/01/14/forbes-india-biocon-pfizer-pharmaceuticals-deal-boost.html
- [Bloomberg, 2019] India Election Dates Set in April as Modi Battles Congress Party (references Sunil Arora) | https://www.bloomberg.com/news/articles/2019-03-10/india-announces-poll-dates-as-modi-fights-to-retain-power
- [Inc42] CrisprBits - A Funded Health Tech Startup Based Out Of New Delhi (references team size) | https://inc42.com/company/crisprbits/
- [Digital Health News] CrisprBits partners with Molbio Diagnostics | https://www.digitalhealthnews.in/index.php/company-news/healthtech-startup-crisprbits-partners-with-molbio-diagnostics-to-develop-crispr-based-pocts
- [Crunchbase] CrisprBits - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/crisprbits
- [crisprbits.com] Team page reference for Bharat Jobanputra
- [Business Standard, 2025] Article referencing Aditya Sarda as co-founder
- [IndiaMedToday, 2025] CrisprBits to scale PathCrisp molecular diagnostics platform